Research records indexed for Pramlintide
This page carries 12 of the 484 records that the literature query returned for Pramlintide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 472 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Pramlintide.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients pmid:33772845 | 2021 | Research Support, Non-U.S. Gov't, research-article | human trial | Not stated | Indexed as research support, non-u.s. gov't, research-article. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Trigeminal Ganglion; Mice, Inbred C57BL; Rats, Sprague-Dawley; Calcitonin Gene-Related Peptide; Cross-Over Studies. |
| A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial pmid:31974099 | 2020 | Research Support, Non-U.S. Gov't, Randomized Controlled Trial | human trial | Not stated | Indexed as research support, non-u.s. gov't, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Diabetes Mellitus, Type 1; Insulin; Blood Glucose; Hypoglycemic Agents; Insulin Infusion Systems. |
| A co-formulation of supramolecularly stabilized insulin and pramlintide enhances mealtime glucagon suppression in diabetic pigs pmid:32393892 | 2020 | Research Support, Non-U.S. Gov't, research-article | rodent | Not stated | Indexed as research support, non-u.s. gov't, research-article. study model from MeSH "Rats, Sprague-Dawley". subject headings: Swine; Rats, Sprague-Dawley; Diabetes Mellitus, Experimental; Polyethylene Glycols; Imidazoles. |
| Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide pmid:27208332 | 2016 | Clinical Trial, research-article | human trial | Not stated | Indexed as clinical trial, research-article. study model from MeSH "Humans" with publication type "clinical trial". subject headings: Diabetes Mellitus, Type 1; Hyperglycemia; Insulin; Blood Glucose; Hypoglycemic Agents. |
| Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition pmid:24239383 | 2014 | Research Support, Non-U.S. Gov't | rodent | Not stated | Indexed as research support, non-u.s. gov't. study model from MeSH "Mice". subject headings: Hippocampus; Neurons; Cells, Cultured; Alzheimer Disease; Disease Models, Animal. |
| Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors pmid:24169554 | 2014 | Research Support, Non-U.S. Gov't | rodent | Not stated | Indexed as research support, non-u.s. gov't. study model from MeSH "Rats". subject headings: COS Cells; Calcitonin; Peptide Fragments; Receptors, Calcitonin; Hypoglycemic Agents. |
| Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes pmid:22815298 | 2012 | Research Support, Non-U.S. Gov't, research-article | human trial | Not stated | Indexed as research support, non-u.s. gov't, research-article. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Diabetes Mellitus, Type 1; Insulin; Blood Glucose; Hypoglycemic Agents; Pancreas, Artificial. |
| Pramlintide and the treatment of diabetes: a review of the data since its introduction pmid:21564002 | 2011 | Review | other | Not stated | Indexed as review. study model from MeSH "Humans" with no interventional publication type. subject headings: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Drug Interactions; Islet Amyloid Polypeptide. |
| The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis pmid:21199269 | 2011 | Meta-Analysis, Systematic Review | other | Not stated | Indexed as meta-analysis, systematic review. study model from MeSH "Humans" with no interventional publication type. subject headings: Diabetes Mellitus, Type 2; Hypoglycemia; Obesity; Body Weight; Incidence. |
| Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial pmid:20094043 | 2010 | Research Support, Non-U.S. Gov't, Multicenter Study | human trial | Not stated | Indexed as research support, non-u.s. gov't, multicenter study. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Obesity; Weight Loss; Phentermine; Cyclobutanes; Appetite Depressants. |
| Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy pmid:19521351 | 2009 | research-article, Multicenter Study | human trial | Not stated | Indexed as research-article, multicenter study. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Obesity; Weight Loss; Amyloid; Leptin; Receptors, Peptide. |
| Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity pmid:18753666 | 2008 | research-article, Randomized Controlled Trial | human trial | Not stated | Indexed as research-article, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Weight Loss; Amyloid; Placebos; Hypoglycemic Agents; Body Mass Index. |
Where this page sits
Compound page: Pramlintide. Class: Amylin and amylin receptor agonists.
Retrieved 2026-10-12.
Sources
- PubChem Compound Summary for CID 70691388, Pramlintide. PubChem, National Library of Medicine (2026). pubchem:70691388
- Drugs@FDA application register query for this compound, 1 application(s) returned: NDA021332. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:pramlintide
- Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Current pharmaceutical design (2001). pmid:11472273
- A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes care (2002). pmid:11919132
- Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes care (2003). pmid:12610038
- Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabetic medicine : a journal of the British Diabetic Association (2004). pmid:15498087
- A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes care (2006). pmid:17003291
- Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes technology & therapeutics (2002). pmid:12017421
- Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obesity research (2004). pmid:15090634
- Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia (2005). pmid:15843914
- Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. The Journal of clinical endocrinology and metabolism (2007). pmid:17504894
- Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes care (2008). pmid:18753666
- Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring, Md.) (2009). pmid:19521351
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.